Advertisement
Advertisement
SGMT
Sagimet Biosciences Inc. Series A Common Stock
7.71
USDSponsored
+0.07
+0.92%
May 08, 16:00 UTC -4
Closed
After-Market
7.66
-0.05
-0.70%
SGMT Earnings Reports
Positive Surprise Ratio
SGMT beat 7 of 11 last estimates.
64%
Next Report
Date of Next Report
May 20, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.39
Implied change from Q4 25 (Revenue/ EPS)
--
/+39.29%
Implied change from Q1 25 (Revenue/ EPS)
--
/-30.36%
Sagimet Biosciences Inc. Series A Common Stock earnings per share and revenue
On Mar 11, 2026, SGMT reported earnings of -0.28 USD per share (EPS) for Q4 25, beating the estimate of -0.41 USD, resulting in a 30.10% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.80% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.39 USD, with revenue projected to reach -- USD, implying an increase of 39.29% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
FAQ
What were Sagimet Biosciences Inc. Series A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.28, beating estimates by 30.1%, and revenue of $0.00, 0% as expectations.
How did the market react to Sagimet Biosciences Inc. Series A Common Stock's Q4 2025 earnings?
The stock price moved up 3.8%, changed from $5.53 before the earnings release to $5.74 the day after.
When is Sagimet Biosciences Inc. Series A Common Stock expected to report next?
The next earning report is scheduled for May 20, 2026.
What are the forecasts for Sagimet Biosciences Inc. Series A Common Stock's next earnings report?
Based on --
analysts, Sagimet Biosciences Inc. Series A Common Stock is expected to report EPS of -$0.39 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement